Regulatory agilities and regulatory processes
During the pandemic, agilities in regulatory processes have been key to allowing safe and effective COVID-19 and non-COVID-19 related medicines and vaccines to be rapidly developed, assessed, approved, and accessed.
Extraordinary measures have been applied by National Regulatory Authorities
(NRAs) and the pharmaceutical industry to face the challenges brought by the COVID19 pandemic emergency. A variety of agilities in regulatory processes have been key to allow the rapid development, assessment, approval of and access to safe and effective COVID-19 and non-COVID-19 related medicines and vaccines.
This policy briefing summarizes trends in reported experiences (from primary and
secondary research) in the use of these agilities observed since the start of the
pandemic, some reported challenges to their implementation and forward-looking
recommendations, whether to prepare for the next pandemic or to strengthen
standard normative processes to accelerate patient access to safe and effective
medicines and vaccines.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
Related news and resources
Navigating the ECOWAS Joint Assessment Procedure
The ECOWAS Joint Assessment Procedure is a collaborative initiative among 15 National Regulatory Agencies in West Africa that ensures harmonized and streamlined market authorization of medical products across the region. This infographic provides an overview of key steps and timelines applicants need to bear in mind during the Joint Assessment Procedure.
Read more
Comment on WHO announcement that COVID-19 no longer a Public Health Emergency of International Concern
IFPMA comment on WHO announcement that COVID-19 no longer constitutes a PHEIC.
Read moreRegistration of multiple manufacturing sites in one product license
In a joint position paper, EFPIA, IFPMA and Vaccines Europe urge all countries to adopt a ‘multiple-site-to-one-license’ approach for registrations, in line with WHO and other guidelines. This will result in a reduction of duplicate work for all stakeholders, help to build agility and speed in supply chain management and improve patient access to medicines and vaccines.
Read more